ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
Qiang LiAlexis W DamishZoë FrazierDavid LiuElizaveta ReznichenkoAtanas KamburovAndrew BellHuiyong ZhaoEmmet J JordanS Paul GaoJennifer MaPhilip H AbboshJoaquim BellmuntElizabeth R PlimackJean-Bernard LazaroDavid B SolitDean BajorinJonathan E RosenbergAlan D D'AndreaNadeem RiazEliezer M Van AllenGopa IyerKent W MouwPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Our data support a direct role for ERCC2 mutations in driving cisplatin response, define the functional landscape of ERCC2 mutations in bladder cancer, and provide an opportunity to apply combined genomic and functional approaches to prospectively guide therapy decisions in bladder cancer.See related commentary by Grivas, p. 907.